Dr. Srinivas Panja, MD (he/him) is an Endocrinologist in Kingwood, TX with over 15 years of experience. What is your opinion of Dr. Srinivas Panja, MD? Rate this provider below so other people can make informed decision.
Over 15 Years of Experience
Many providers receive payments from medical companies such as pharmaceutical companies and medical device companies. These payments can range from small amounts for meals to large consulting fees. We provide this information in order to make healthcare system more transparent. Between 2014 and 2020 Dr. Srinivas Panja, MD has received over $228,004 which includes payments from the following companies:
$181,194.89 from sanofi-aventis U.S. LLC
$30,503.61 from LILLY USA, LLC
$3,717.48 from Corcept Therapeutics
$3,644.25 from Horizon Pharma plc
$2,628.04 from Dexcom, Inc.
$1,344.19 from Novo Nordisk Inc
$831.74 from AstraZeneca Pharmaceuticals LP
$495.04 from Medtronic MiniMed, Inc.
$409.53 from Shire North American Group Inc
$333.92 from AbbVie, Inc.
$269.68 from Tandem Diabetes Care, Inc.
$259.21 from Takeda Pharmaceuticals America, Inc.
$239.83 from Janssen Pharmaceuticals, Inc
$207.54 from Merck Sharp & Dohme Corporation
$183.64 from Pfizer Inc.
$162.30 from INSULET CORPORATION
$155.24 from Companion Medical, Inc.
$143.00 from Senseonics, Incorporated
$133.11 from Boehringer Ingelheim Pharmaceuticals, Inc.
$101.88 from MannKind Corporation
Payments received by Dr. Srinivas Panja, MD were from the following categories:
$188,183.25 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Do you have any questions about your diabetes condition or general questions about diabetes? You can now post those questions in DiabetesIQ Forum and have our diabetes experts answer your questions for FREE! Yes, there is absolutely no catch! - Registration only takes a few seconds and it's FREE. No credit card needed. You can ask any number of diabetes questions, all for FREE! Register today and join the conversation!